Caricamento...
Dabrafenib and trametinib in BRAFV600E mutated glioma
BRAFV600E mutations have been identified in a number of glioma subtypes, most frequently in pleomorphic xanthoastrocytoma, ganglioglioma, pilocytic astrocytoma, and epithelioid glioblastoma. Although the development of BRAF inhibitors has dramatically improved the clinical outcome for patients with...
Salvato in:
| Pubblicato in: | CNS Oncol |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Future Medicine Ltd
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6004887/ https://ncbi.nlm.nih.gov/pubmed/28984141 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/cns-2017-0006 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|